Use of mirtazapine in the treatment of canine behaviour problems
Canine behaviour problems seen by speciality behavioural medicine services often involve chronic anxiety disorders that have resulted in maladaptation of the individual to its environment. Common stressors include the presence of other individuals (other dogs or people), noise and being alone. The treatment of these behavioural problems usually includes a combination of behaviour modification, environmental modification and biological therapies. Within the latter, anxiolytic drugs such as clomipramine or fluoxetine have proven useful.
In this retrospective study the authors present 32 cases that were treated with the anxiolytic drug mirtazapine, which is widely used in human medicine but has not previously been reported for the treatment of behavioural problems in dogs (although it is marketed as an appetite stimulant in cats).
The case records for Ethoclinic Valencia were searched between July 2016 and December 2022 to identify all dogs that received mirtazapine for behavioural problems. Only those for which mirtazapine was the monotherapy from the beginning to the end of treatment were included in the case population (n = 32)
Eighty-one percent of dogs that presented with a behavioural problem showed improvement and suspected adverse effects were mild and tolerable.
Mirtazapine appears to be a suitable and safe option for the treatment of anxiety-related behavioural problems in this population of dogs. Further studies are required to isolate this result from the other therapeutic measures and to compare its efficacy with other drugs.
“Use of mirtazapine in the treatment of canine behaviour problems: A review of 32 cases”. Juan Argüelles, et al. Vet Rec. 2023 Dec 11:e3670. doi: 10.1002/vetr.3670.
Source: https://bvajournals.onlinelibrary.wiley.com/doi/full/10.1002/vetr.3670
Comments
Related Articles
More news
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment